aTyr Pharma, Inc.
$0.85
▼
-0.46%
2026-04-21 05:28:01
atyrpharma.com
NCM: ATYR
Explore aTyr Pharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$83.68 M
Current Price
$0.85
52W High / Low
$7.29 / $0.64
Stock P/E
—
Book Value
$0.69
Dividend Yield
—
ROCE
-99.71%
ROE
-1.08%
Face Value
—
EPS
$-0.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
58
Beta
0.65
Debt / Equity
17.88
Current Ratio
5.3
Quick Ratio
5.3
Forward P/E
-2.07
Price / Sales
429.57
Enterprise Value
$14.77 M
EV / EBITDA
-0.19
EV / Revenue
77.75
Rating
Hold
Target Price
$4.36
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Reviva Pharmaceuticals Holdings, Inc. | $0.91 | — | $10.89 M | — | -233.59% | -4.2% | $23.2 / $0.59 | $1.47 |
| 2. | Theravance Biopharma, Inc. | $16.72 | 8.29 | $877.44 M | — | -0.81% | 44.84% | $21.03 / $8.33 | $5.81 |
| 3. | Kairos Pharma, Ltd. | $0.63 | — | $13.1 M | — | -87.87% | -97.99% | $2.11 / $0.4 | $0.37 |
| 4. | Quince Therapeutics, Inc. | $1.27 | — | $22.33 M | — | -33.74% | -2.48% | $45.5 / $0.8 | $0.02 |
| 5. | Oculis Holding AG | $28.61 | — | $1.64 B | — | -41% | -73.45% | $30.68 / $16 | $4.24 |
| 6. | Sarepta Therapeutics, Inc. | $21.42 | — | $2.24 B | — | -29.18% | -53.47% | $64.8 / $10.42 | $10.87 |
| 7. | Bicara Therapeutics Inc. | $23.47 | — | $1.57 B | — | -38.7% | -30.89% | $24.25 / $7.8 | $7.37 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0.19 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -14.8 M | -26.75 M | -20.31 M | -15.77 M | -15.82 M | — |
| Net Profit | -13.96 M | -25.74 M | -19.53 M | -14.88 M | -14.97 M | — |
| EPS in Rs | -0.14 | -0.26 | -0.2 | -0.15 | -0.15 | -0.23 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.19 M | 0.23 M | 0.35 M | 10.39 M |
| Operating Profit | -77.63 M | -67.91 M | -54.92 M | -46.4 M |
| Net Profit | -74.12 M | -64.02 M | -50.39 M | -45.34 M |
| EPS in Rs | -0.76 | -0.65 | -0.51 | -0.46 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 93 M | 96.83 M | 120.65 M | 95.79 M |
| Total Liabilities | 25.71 M | 27 M | 30.18 M | 24.5 M |
| Equity | 67.48 M | 70.02 M | 90.66 M | 71.46 M |
| Current Assets | 80.24 M | 81.95 M | 102.99 M | 80.87 M |
| Current Liabilities | 15.15 M | 14.97 M | 16.42 M | 13.86 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -61.99 M | -69.12 M | -33.22 M | -41.89 M |
| Investing CF | -5.05 M | 17.23 M | -20.13 M | 47.24 M |
| Financing CF | 66.01 M | 39.86 M | 66.23 M | 5.45 M |
| Free CF | -62.06 M | -69.18 M | -37.44 M | -43.53 M |
| Capex | -0.08 M | -0.07 M | -4.21 M | -1.64 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -33.43% | -96.6% | — | — |
| Earnings Growth % | -27.06% | -11.14% | — | — |
| Profit Margin % | -27243.83% | -14274.5% | -436.53% | — |
| Operating Margin % | -28899.57% | -15557.79% | -446.79% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -28244.26% | -14781.3% | -430.47% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.